21,000 Shares in Harrow, Inc. (NASDAQ:HROW) Acquired by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. purchased a new stake in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 21,000 shares of the company's stock, valued at approximately $559,000. Hussman Strategic Advisors Inc. owned about 0.06% of Harrow as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new stake in Harrow in the 4th quarter worth approximately $25,000. Tower Research Capital LLC TRC raised its holdings in shares of Harrow by 769.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after acquiring an additional 1,462 shares during the period. Aquatic Capital Management LLC purchased a new position in shares of Harrow during the 4th quarter worth $78,000. Federated Hermes Inc. purchased a new position in shares of Harrow during the 4th quarter worth $214,000. Finally, Maridea Wealth Management LLC acquired a new stake in shares of Harrow during the 4th quarter worth about $222,000. 72.76% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Cantor Fitzgerald assumed coverage on Harrow in a research note on Friday, July 11th. They set an "overweight" rating and a $76.00 target price for the company. B. Riley reduced their price objective on Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. BTIG Research assumed coverage on Harrow in a research note on Thursday, June 12th. They issued a "buy" rating and a $62.00 price objective for the company. William Blair assumed coverage on Harrow in a research note on Tuesday, June 10th. They issued an "outperform" rating for the company. Finally, HC Wainwright boosted their price objective on Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a research note on Monday, May 12th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $63.83.

Harrow Stock Performance

Harrow stock traded down $0.97 during trading hours on Tuesday, hitting $36.11. The stock had a trading volume of 488,345 shares, compared to its average volume of 502,315. The company has a 50-day moving average of $30.34 and a two-hundred day moving average of $28.79. The company has a quick ratio of 0.85, a current ratio of 0.91 and a debt-to-equity ratio of 2.01. The company has a market cap of $1.32 billion, a PE ratio of -64.48 and a beta of 0.41. Harrow, Inc. has a fifty-two week low of $20.85 and a fifty-two week high of $59.23.

Harrow (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.40). The company had revenue of $47.83 million during the quarter, compared to the consensus estimate of $57.00 million. Harrow had a negative return on equity of 25.01% and a negative net margin of 10.19%. On average, equities research analysts anticipate that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.